The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis



Status:Active, not recruiting
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - Any
Updated:6/22/2018
Start Date:March 16, 2017
End Date:January 30, 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis: A Chart Review Study

The purpose of this study is to investigate the value of Orencia in rapidly progressing
Rheumatoid Arthritis (RA).


Inclusion Criteria:

- 18 years of age at enrollment

- Confirmed diagnosed with RA

- Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab
with a record of the start date at the practice site

Exclusion Criteria:

- Does not have at least 1 or more poor RA prognostic factor: Evidence of joint
erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP
levels, Increased ESR levels

- Was followed at the site for less than 1 year since biologic treatment initiation

- Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative
colitis, psoriatic arthritis, anal fistula

Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Local Institution
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials